FDANews
FDAnews Drug Daily Bulletin

LODH RAISES NOVARTIS TARGET TO CHF100

May 15, 2006

Lombard Odier Darier Hentsch raised its target for Novartis (NVS) to CHF100 from CHF85. Says the new target is still a base case, not incorporating any early-stage pipeline drugs. "Currently, valuation does not reflect accelerating growth prospects for the Novartis flagship pharmaceuticals division," LODH says. "
Newratings